Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT03515798
Title Study of Immunotherapy in Combination With Chemotherapy in HER2-negative Inflammatory Breast Cancer (PELICAN)
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Institut Paoli-Calmettes

Her2-receptor negative breast cancer


Cyclophosphamide + Epirubicin + Paclitaxel

Cyclophosphamide + Epirubicin + Paclitaxel + Pembrolizumab

Age Groups: senior | adult
Covered Countries FRA | BEL

No variant requirements are available.